Role of phosphoinositides in neuronal membrane traffic and neurodegeneration

磷酸肌醇在神经元膜交通和神经变性中的作用

基本信息

  • 批准号:
    8372410
  • 负责人:
  • 金额:
    $ 34.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-01 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Intracellular signaling lipids control a large variety of cellular processes, including membrane trafficking, cytoskeletal dynamics, transport across membranes and signal transduction. Not surprisingly, lipid signaling and alterations thereof are increasingly linked to human disease. Alzheimer's disease (AD) is one such disorder in which lipid dyshomeostasis and membrane trafficking defects are believed to play a critical role. This concept is easily reconciled with the fact that the main molecular players in AD, including amyloid precursor protein (APP) and the ?-, ?- and ?-secretases, are all transmembrane proteins (or protein complexes) that traffic in cells and exert their functions at or within cellulr membranes. Our working hypothesis is that specific lipid changes may drive or mediate fundamental aspects of AD pathogenesis. Systems-based approaches, such as "lipidomics", are emerging as a powerful tool to profile cells, tissues or organisms in a diseased state, providing both an unbiased and comprehensive picture of lipid alterations potentially linked to pathogenicity. To better understand the link between lipid signaling defects and AD pathogenesis, we have recently conducted a lipidomic analysis of brain samples derived from three transgenic animal models of familial AD as well as three independent brain regions from patients with late-onset AD. We found that out of 330 lipid species analyzed, only one lipid species was significantly reduced in AD-affected brain regions in mice (forebrain) and men (entorhinal and prefrontal cortex): phosphatidylinositol-3-phosphate (PI3P). PI3P is a phosphoinositide primarily synthesized by lipid kinase Vps34 and acts as a master regulator of the endosomal and autophagy pathways. PI3P controls the recruitment of a variety of compartment-specific effectors harboring PI3P binding modules, such as FYVE or PX domains. We found that knocking down/out Vps34 recapitulates salient features linked to AD pathogenesis, namely (i) enlarged endosomes; (ii) aberrant endosomal trafficking and processing of the amyloid precursor protein (APP); and (iii) accumulation of autophagy substrates. Additionally, work from others shows that chronic lack of Vps34 in neurons produces neurodegeneration. Altogether, our results have identified PI3P deficiency as a key factor in AD pathogenesis. This proposal focuses on addressing the consequences of disrupting PI3P signaling on two processes that emerge as critical in AD pathogenesis, namely the endosomal trafficking and processing of APP (Aim 1) and neuronal autophagy (Aim 2). It will also assess the impact of PI3P deficiency on the A? and Tau pathologies in vivo (Aim 3). We anticipate that our studies will provide key insights into the biology of APP and Tau as well as a better understanding of the role of lipid dysregulation in AD pathogenesis. PUBLIC HEALTH RELEVANCE: Lipid dysregulation is believed to play an important role in the pathogenesis of Alzheimer's disease (AD). Our lipidomic analyses of brain tissue derived from mouse models of AD and AD-affected individuals have identified phosphatidylinositol-3-phosphate (PI3P) deficiency as a candidate lipid alteration involved in AD pathogenesis. The goal of the proposed studies is to test the role of PI3P and a key enzyme mediating its synthesis, Vps34, in the traffic of amyloid precursor protein and the clearance of tau aggregates.
描述(由申请人提供):细胞内信号传导脂质控制多种细胞过程,包括膜运输、细胞骨架动力学、跨膜转运和信号转导。毫不奇怪,脂质信号传导及其改变越来越多地与人类疾病相关。阿尔茨海默病(AD)是其中脂质稳态异常和膜运输缺陷被认为起关键作用的一种这样的病症。这一概念很容易与AD中的主要分子参与者,包括淀粉样前体蛋白(APP)和β-,?-然后呢?分泌酶是所有跨膜蛋白(或蛋白复合物),其在细胞中运输并在细胞膜处或细胞膜内发挥其功能。我们的工作假设是,特定的脂质变化可能会驱动或介导AD发病机制的基本方面。基于系统的方法,例如“脂质组学”,正在成为描述处于患病状态的细胞、组织或生物体的强大工具,提供了可能与致病性相关的脂质变化的公正而全面的情况。为了更好地了解脂质信号传导缺陷和AD发病机制之间的联系,我们最近对来自三个家族性AD转基因动物模型的脑样本以及来自迟发性AD患者的三个独立脑区域进行了脂质组学分析。我们发现,在分析的330种脂质中,只有一种脂质在小鼠(前脑)和男性(内嗅和前额皮质)的AD影响的大脑区域中显着减少:磷脂酰肌醇-3-磷酸(PI 3 P)。PI 3 P是主要由脂质激酶Vps 34合成的磷酸肌醇,并作为内体和自噬途径的主要调节剂。PI 3 P控制包含PI 3 P结合模块(如FYVE或PX结构域)的多种区室特异性效应物的募集。我们发现敲低/敲除Vps 34概括了与AD发病机制相关的显著特征,即(i)扩大的内体;(ii)淀粉样前体蛋白(APP)的异常内体运输和加工;和(iii)自噬底物的积累。此外,其他人的工作表明,神经元中长期缺乏Vps 34会导致神经变性。总之,我们的研究结果表明,PI 3 P缺乏是AD发病机制的关键因素。该提案的重点是解决在AD发病机制中出现的两个关键过程中破坏PI 3 P信号传导的后果,即APP的内体运输和加工(目的1)和神经元自噬(目的2)。它还将评估PI 3 P缺乏对A?和体内Tau病理学(目的3)。我们预计,我们的研究将为APP和Tau的生物学提供关键见解,并更好地了解脂质失调在AD发病机制中的作用。 公共卫生相关性:脂质失调被认为在阿尔茨海默病(AD)的发病机制中起重要作用。我们的脂质组学分析来自小鼠模型的AD和AD受影响的个人的脑组织已确定磷脂酰肌醇-3-磷酸(PI 3 P)缺乏症作为一个候选人参与AD发病机制的脂质改变。拟议研究的目标是测试PI 3 P和介导其合成的关键酶Vps 34在淀粉样前体蛋白的运输和tau聚集体的清除中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gilbert Di Paolo其他文献

Gilbert Di Paolo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gilbert Di Paolo', 18)}}的其他基金

Advanced Graduate Training Program in Neurobiology & Behavior
神经生物学高级研究生培训计划
  • 批准号:
    9119319
  • 财政年份:
    2015
  • 资助金额:
    $ 34.71万
  • 项目类别:
Deciphering the metabolism of LBPA and its function in the endolysosomal system
解读 LBPA 的代谢及其在内溶酶体系统中的功能
  • 批准号:
    8802927
  • 财政年份:
    2014
  • 资助金额:
    $ 34.71万
  • 项目类别:
Control of liver autophagy by phosphatidic acid signaling
通过磷脂酸信号控制肝脏自噬
  • 批准号:
    8665858
  • 财政年份:
    2013
  • 资助金额:
    $ 34.71万
  • 项目类别:
Control of liver autophagy by phosphatidic acid signaling
通过磷脂酸信号控制肝脏自噬
  • 批准号:
    8533522
  • 财政年份:
    2013
  • 资助金额:
    $ 34.71万
  • 项目类别:
Assessing the effects of Synj1 haploinsufficiency in Alzheimer's disease models
评估 Synj1 单倍体不足对阿尔茨海默病模型的影响
  • 批准号:
    7658997
  • 财政年份:
    2009
  • 资助金额:
    $ 34.71万
  • 项目类别:
Role of PIP2 metabolism imbalance in Down Syndrome
PIP2代谢失衡在唐氏综合症中的作用
  • 批准号:
    7886831
  • 财政年份:
    2008
  • 资助金额:
    $ 34.71万
  • 项目类别:
Role of PIP2 metabolism imbalance in Down Syndrome
PIP2代谢失衡在唐氏综合症中的作用
  • 批准号:
    8101064
  • 财政年份:
    2008
  • 资助金额:
    $ 34.71万
  • 项目类别:
Role of PIP2 metabolism imbalance in Down Syndrome
PIP2代谢失衡在唐氏综合症中的作用
  • 批准号:
    8312615
  • 财政年份:
    2008
  • 资助金额:
    $ 34.71万
  • 项目类别:
Role of PIP2 metabolism imbalance in Down Syndrome
PIP2代谢失衡在唐氏综合症中的作用
  • 批准号:
    7524804
  • 财政年份:
    2008
  • 资助金额:
    $ 34.71万
  • 项目类别:
Role of PIP2 metabolism imbalance in Down Syndrome
PIP2代谢失衡在唐氏综合症中的作用
  • 批准号:
    7678554
  • 财政年份:
    2008
  • 资助金额:
    $ 34.71万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.71万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了